Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott J Pollack

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|January 29, 2005
Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous proteaseScott J Pollack, Huw Lewis
Current Drug Targets. CNS and Neurological Disorders|May 29, 2003
Small molecule Trk receptor agonists and other neurotrophic factor mimeticsScott J Pollack, Sarah J Harper
Drug News & Perspectives|April 5, 2003
Trk Neurotrophin Receptor ActivatorsScott J. Pollack, Sarah J. Harper
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentNorhakim Yahya, Scott J Pollack, Richard Margolin, et al.
Archives of Biochemistry and Biophysics|May 24, 2005
Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitorsMichael Fricker, Philip Lograsso, Semantha Ellis, et al.
Biochemistry|June 18, 2003
Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavagesHuw D Lewis, Blanca I Pérez Revuelta, Alan Nadin, et al.
The Journal of Comparative Neurology|December 24, 2005
Composition of perineuronal nets in the adult rat cerebellum and the cellular origin of their componentsDaniela Carulli, Kate E Rhodes, David J Brown, et al.
Journal of Computer-Aided Molecular Design|July 7, 2011
A comparative study of fragment screening methods on the p38α kinase: new methods, new insightsScott J Pollack, Kim S Beyer, Christopher Lock, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|January 29, 2005
Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous proteaseScott J Pollack, Huw Lewis
Current Drug Targets. CNS and Neurological Disorders|May 29, 2003
Small molecule Trk receptor agonists and other neurotrophic factor mimeticsScott J Pollack, Sarah J Harper
Drug News & Perspectives|April 5, 2003
Trk Neurotrophin Receptor ActivatorsScott J. Pollack, Sarah J. Harper
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentNorhakim Yahya, Scott J Pollack, Richard Margolin, et al.
Archives of Biochemistry and Biophysics|May 24, 2005
Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitorsMichael Fricker, Philip Lograsso, Semantha Ellis, et al.
Biochemistry|June 18, 2003
Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavagesHuw D Lewis, Blanca I Pérez Revuelta, Alan Nadin, et al.
The Journal of Comparative Neurology|December 24, 2005
Composition of perineuronal nets in the adult rat cerebellum and the cellular origin of their componentsDaniela Carulli, Kate E Rhodes, David J Brown, et al.
Journal of Computer-Aided Molecular Design|July 7, 2011
A comparative study of fragment screening methods on the p38α kinase: new methods, new insightsScott J Pollack, Kim S Beyer, Christopher Lock, et al.
Pageof 1